文献速递脊髓损伤康复骨科与运动康复

双膦酸盐治疗与脊髓损伤或疾病患者下肢骨折发生率的关联

Association of Bisphosphonate Therapy With Incident of Lower Extremity Fractures in Persons With Spinal Cord Injuries or Disorders.
PubMed 文献 · Arch Phys Med Rehabil · 2020-01-18

本研究基于美国退伍军人事务部2005至2015年数据库,采用倾向匹配病例对照分析,纳入7989名男性和849名女性脊髓损伤或疾病患者,评估双膦酸盐处方与下肢骨折风险的关系。结果显示,在男性和女性中双膦酸盐处方与下肢骨折均无显著关联(男性OR 1.04,95%CI 0.62-1.77;女性OR 1.02,95%CI 0.28-3.75),提示该药物对骨折风险无明显影响,需随机对照试验进一步验证。

要点

  • 双膦酸盐处方与男性下肢骨折无显著关联(OR 1.04,95%CI 0.62-1.77)。
  • 女性中双膦酸盐与下肢骨折亦无显著关联(OR 1.02,95%CI 0.28-3.75)。
  • 男性亚组分析(依从、联合用药等)均显示无显著关联。

核心结论

  • 在创伤性脊髓损伤男性及创伤性脊髓损伤或疾病女性中,双膦酸盐治疗骨质疏松似乎不显著影响骨折风险。
  • 需要足够效能的随机对照试验明确双膦酸盐在该人群中的骨折预防效果。

研究设计与样本

  • 共纳入7989名男性和849名女性脊髓损伤或疾病患者(N=8838)。
  • 病例包括267名男性和59名女性有双膦酸盐处方者,按倾向匹配最多4名对照。

主要发现

  • 男性双膦酸盐处方与下肢骨折无显著关联(OR 1.04;95%CI 0.62-1.77)。
  • 女性双膦酸盐处方与下肢骨折无显著关联(OR 1.02;95%CI 0.28-3.75)。
  • 男性中依从双膦酸盐治疗者无显著关联(OR 1.25;95%CI 0.73-2.16)。
  • 男性中联合使用维生素D和钙及双膦酸盐者无显著关联(OR 1.05;95%CI 0.57-1.96)。
  • 男性中研究期间不同日期发生超过1次骨折者无显著关联(OR 0.13;95%CI 0.02-1.16)。

关键数值与推荐

  • 男性双膦酸盐处方与下肢骨折的OR为1.04(95%CI 0.62-1.77)。
  • 女性双膦酸盐处方与下肢骨折的OR为1.02(95%CI 0.28-3.75)。
  • 男性依从双膦酸盐治疗的OR为1.25(95%CI 0.73-2.16)。
  • 男性联合使用维生素D和钙及双膦酸盐的OR为1.05(95%CI 0.57-1.96)。
  • 男性不同日期超过1次骨折的OR为0.13(95%CI 0.02-1.16)。

临床怎么用

  • 针对脊髓损伤或疾病患者,双膦酸盐治疗骨质疏松未显示显著降低下肢骨折风险。
  • 临床需综合评估骨折风险,不能仅依赖双膦酸盐预防下肢骨折。
  • 建议关注该高危人群的新型骨折预防药物研究进展。

局限性

  • 本研究为观察性病例对照分析,无法确立因果关系。
  • 结论需足够效能的随机对照试验证实双膦酸盐的骨折预防效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between prescriptions for bisphosphonates; calcium and vitamin D supplements; and receipt of dual-energy x-ray absorptiometry (DXA) screening, and incident fracture risk in men and women with a spinal cord injury (SCI) or disorder (SCID). DESIGN: Propensity-matched case-control analyses. SETTING: United States Veterans Affairs (VA) facilities. PARTICIPANTS: A total of 7989 men and 849 women with an SCID included in VA administrative databases between October 1, 2005 and October 1, 2015 were identified (N=8838). Cases included 267 men and 59 women with a bisphosphonate prescription propensity matched with up to 4 controls. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Incident lower extremity fractures. RESULTS: There was no significant association between prescriptions for bisphosphonates and incident lower extremity fractures in men (odds ratio [OR], 1.04; 95% confidence interval [CI], 0.62-1.77) or women (OR, 1.02; 95% CI, 0.28-3.75). In men, similar null associations were seen among those who were adherent to bisphosphonate therapy (OR, 1.25; 95% CI, 0.73-2.16), were concomitant users of vitamin D and calcium and a bisphosphonate (OR, 1.05; 95% CI, 0.57-1.96), had more than 1 fracture on different dates during the study period (OR, 0.13; 95% CI, 0.02-1.16) and in those who had undergone DXA testing prior to the date of the bisphosphonate prescription and incident fracture (OR, 1.26; 95% CI, 0.69-2.32). CONCLUSIONS: In men with a traumatic SCI and women with a traumatic SCID, bisphosphonate therapies for osteoporosis do not appear to significantly affect fracture risk. Adequately powered randomized controlled trials are needed to definitively demonstrate efficacy of bisphosphonates for fracture prevention in this population. There is a compelling need to identify new medications to prevent fractures in this high-risk population.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Carbone LD, Gonzalez B, Miskevics S, et al. Association of Bisphosphonate Therapy With Incident of Lower Extremity Fractures in Persons With Spinal Cord Injuries or Disorders. Arch Phys Med Rehabil. 2020. PMID: 31958428. doi:10.1016/j.apmr.2019.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。